Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued a corrected filing for its corporate spin-off decision originally disclosed on May 22, 2025, updating the English name of the newly established entity and postponing the overall spin-off schedule—including the EGM date (Oct 17), spin-off date (Nov 1), trading suspension period, and listing change and relisting date (Nov 24)—by approximately one month.
📊 [Key Disclosure Details & Financial Figures]
- Original Filing & Submission Date: Report on Material Matters (Decision on Corporate Spin-off) (Submitted on May 22, 2025)
- Reason for Correction: Schedule adjustments and revision of the newly established company’s English trade name
- Comparison of Key Corrections:
- Newly Established Company English Name: (Before) Samsung Episholdings Co.,Ltd → (After) SAMSUNG EPIS HOLDINGS CO.,LTD.
- Scheduled EGM Date: (Before) September 16, 2025 → (After) October 17, 2025
- Spin-off Effective Date: (Before) October 1, 2025 → (After) November 1, 2025
- Trading Suspension Period: (Before) September 29, 2025 – October 28, 2025 → (After) October 30, 2025 – November 21, 2025
- New Share Allotment Record Date: (Before) September 30, 2025 → (After) October 31, 2025
- Expected Listing Change / Relisting Date for Shares: (Before) October 29, 2025 → (After) November 24, 2025
- General Meeting for Completion Reporting & Registration Date: (Before) October 1, 2025 → (After) November 3, 2025
- Spin-off Overview & Key Figures (Unchanged):
- Spin-off Method: Simple Spin-off (Demerger)
- Corporate Structure & Listing Status:
- Surviving Company: Samsung Biologics Co., Ltd. (CDMO Business Division) – Subject to Listing Change (KOSPI)
- Newly Established Company: SAMSUNG EPIS HOLDINGS CO.,LTD. (provisional) (Holding & Investment Division for subsidiaries like Samsung Bioepis) – Subject to Relisting (KOSPI)
- Spin-off Ratio: Surviving Company 0.6503913 : Newly Established Company 0.3496087
- Financials of Surviving Entity (As of March 31, 2025): Total Assets KRW 9.98T, Total Liabilities KRW 3.74T, Total Equity KRW 6.24T, Capital Stock KRW 115.7B
- Financials of New Entity (As of March 31, 2025): Total Assets KRW 3.37T, Total Liabilities KRW 8.95B, Total Equity KRW 3.36T, Capital Stock KRW 62.2B
- Other Important Investment Details:
- Appraisal rights for dissenting shareholders do not apply due to the nature of a simple spin-off with relisting plans.
- Both entities will remain jointly and severally liable for obligations incurred prior to the spin-off.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Execution of Postponed Spin-off Schedule and EGM Results
This correction disclosure reflects an overall postponement of Samsung Biologics’ spin-off timeline by approximately one month.
Monitoring the voting results at the rescheduled EGM (October 17, 2025) and checking whether subsequent milestones—such as the trading suspension, listing change of the surviving company, and relisting of the new entity (scheduled for November 24, 2025)—proceed as planned is essential.
Relevant developments can be verified in future disclosures regarding the EGM results, trading suspension notices, and official listing filings.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
